1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year

GIP Receptor Antagonism Versus Agonism On Trial

 
• By Mandy Jackson

Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.

Weight scale instrument for measurement balance of people body concept
Amgen's Phase II MariTide data are expected in late 2024 • Source: Shutterstock

Amgen, Inc. has taken a divergent path with its obesity drug candidate maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist, which has delivered intriguing weight loss in a Phase I clinical trial despite differing from Eli Lilly and Company’s Zepbound (tirzepatide), which agonizes both GLP-1 and GIP. Phase II data for MariTide are not expected until late 2024, leaving observers impatient for data clarifying Amgen’s approach.

Key Takeaways

  • Amgen’s Q4 earnings call was dominated by questions about the company’s maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist.

  • ...

While Amgen announced a 20% increase in Q4 revenue to $8.2bn, thanks to the closing of its $27.8bn acquisition of Horizon Therapeutics plc early in the quarter and gains...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.